Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Busy Times and Divergent Strategies for Celtic Pharma's Follow-On Funds

This article was originally published in Start Up

Executive Summary

The various Celtic funds (there are three, with two sprouting from the original Celtic Pharma I Holdings established in 2004) posted a very busy January, closing deals involving Kolltan Pharmaceuticals Inc., Cantab Pharmaceuticals PLC, Inspiration Biopharmaceuticals Inc. and PolyTherics Ltd. But the details of these transactions help illustrate how the two actively investing successor funds have established fundamentally different investment strategies, even if those strategies can overlap at times.

Related Content

Kolltan Approaching First IND Submission For RTK-Targeted Oncology Drug Candidate
Celtic Pours More Private Equity Into The Promise Of Antibody-Drug Conjugates
Renewing Old Ties, Celtic Therapeutics Leads $10 Million Series B For Kolltan
Finding Inspiration: Ipsen Builds Fourth Specialist Franchise With Hemophilia Deal
Celtic Pharma Sees a Role for Private Equity in Biotech
Celtic Pharma Sees a Role for Private Equity in Biotech


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts